NCT06429137

A Study in Healthy Men to Test How Well Different Doses of BI 3731579 Are Tolerated

A Partially Randomised, Single-blind, Placebo-controlled Trial to Investigate Safety, Tolerability, and Pharmacokinetics of Single Rising Doses of BI 3731579 Administered as Tablet to Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 63 (actual)
• Sponsor: Boehringer Ingelheim · Industry
• Sex: Male
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 3731579 in healthy male subjects.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	BI 3731579	BI 3731579
DRUG	Matching placebo to BI 3731579	Matching placebo to BI 3731579

Timeline

• Start date: 2024-07-08
• Primary completion: 2025-05-19
• Completion: 2025-05-27
• First posted: 2024-05-24
• Last updated: 2025-06-11

Locations

1 site across 1 country: Germany